Guidelines developed collaboratively by the American Society of Clinical Oncology and the National Comprehensive Cancer Network offer clinicians recommendations for assessment and management of side effects related to immune checkpoint inhibitors.
The Oncologic Drugs Advisory Committee held its first session since President Trump’s inauguration, with a two-day, back-to-back marathon meeting, signaling a return to business at FDA after significant upheaval at the agency.
